Alector Inc (STU:0Z2)
€ 3.98 -0.02 (-0.5%) Market Cap: 391.41 Mil Enterprise Value: -93.80 Mil PE Ratio: 0 PB Ratio: 2.37 GF Score: 62/100

Alector Inc to Present to Discuss Data Presented at 2021 Clinical Trials on Alzheimer's Disease Meeting Transcript

Nov 12, 2021 / 09:00PM GMT
Release Date Price: €19.4 (-9.35%)
Operator

Good day, and thank you for standing by. Welcome to the Alector call to discuss recent data presentation conference call. (Operator Instructions)

I would now like to hand the conference over to your first speaker today, Michelle Corral, Vice President of Communications and Investor Relations. Please go ahead.

Michelle Corral
Alector, Inc. - VP of Communications & IR

Thank you, Laurie. Good afternoon, and thank you all for joining us on today's call. I'm Michelle Corral, Alector's Vice President of Corporate Communications and Investor Relations. Today, we will be reviewing data presented this week at the Clinical Trials for Alzheimer's disease or CTAD and the Society for Immunotherapy of Cancer or SITC meeting. We have data this week from 4 of Alector's pipeline programs, and each of those presentations is available on the Investors section of the Alector website.

On today's call, we have CEO and Co-Founder, Dr. Arnon Rosenthal; Dr. Sam Jackson, our Chief Medical Officer; as well as Dr. Daniel Maslyar, our VP of Clinical Drug Development

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot